Funded Biotechnology Startups in Palo Alto
Among the 31 most recent biotechnology funding entries in Palo Alto, disclosed round sizes show a clear size split: the largest disclosed amount is Kodiak…
Among the 31 most recent biotechnology funding entries in Palo Alto, disclosed round sizes show a clear size split: the largest disclosed amount is Kodiak Sciences’ $184M round on 2025-12-16, and it is followed by BridgeBio Pharma’s $500M (2025-02-25) and two $500M debt rounds (BridgeBio Pharma and Ascendis Pharma’s Post-IPO Debt on 2022-03-24). Apart from those upper-end outliers (including BBOT’s $261M on 2025-08-11), many rounds cluster well below $100M, such as Juvena Therapeutics at $34M (2026-01-12) and Countable Labs at $26M (2026-05-28).
Timing also clusters: 8 of the 31 rows fall between 2025-11-10 and 2026-06-17, with multiple entries in January 2026 (e.g., Ukko $45M on 2026-01-08; Avenue Biosciences $7M on 2026-01-12; Juvena Therapeutics $34M on 2026-01-12). Stage reporting is frequently not standardized—“Series Unknown” appears in multiple rows (and some amounts are “undisclosed”), and stage labels like Series A and Series B recur across the 2021-05-18 to 2026-06-17 window.
Most recent rounds
31 shownRelated listings
Frequently asked
What’s the biggest disclosed funding amount in this Palo Alto biotech list, and does it stand apart from the rest?
The largest disclosed amount is BridgeBio Pharma’s $500M round dated 2025-02-25 (with Ascendis Pharma also at $500M on 2022-03-24 as Post-IPO Debt). Outside those $500M outliers, the next-highest disclosed amounts include BBOT’s $261M (2025-08-11) and Kodiak Sciences’ $184M (2025-12-16), while several entries sit far lower, such as Epalex at $1M (2025-11-10) and Greenstone Biosciences at $3M (2023-09-12).
Are there clusters of biotech funding activity by time in the most recent entries shown?
Yes. Eight of the 31 rows fall between 2025-11-10 and 2026-06-17, and January 2026 alone includes multiple closings: Ukko ($45M) on 2026-01-08, Avenue Biosciences ($7M) on 2026-01-12, and Juvena Therapeutics ($34M) on 2026-01-12. The list also shows a broader run from 2021-05-18 (Artificial $22M) to 2026-06-17 (Spot Biosystems $40M).
How often is the stage unclear or the amount undisclosed, and does that affect comparing deal sizes?
Stage clarity is inconsistent: “Series Unknown” appears repeatedly (e.g., Kodiak Sciences 2025-12-16; BBOT 2025-08-11; BridgeBio Pharma 2025-02-25), and there are also rows where the amount is explicitly “undisclosed” (Myome on 2025-12-11; HepaTx on 2025-05-20; Amygdala Neuroscience on 2024-05-14; DigPath on 2024-04-10). Because of those gaps, size comparisons are most reliable within the disclosed subset.
Which stages recur most in this dataset of Palo Alto biotech rounds?
Series A and Series B both show up multiple times, with Series A examples including Pumpkinseed Technologies ($20M, 2026-05-05), Biostate AI ($12M, 2025-05-20), and ImpriMed ($23M, 2023-12-19). Series B examples include Juvena Therapeutics ($34M, 2026-01-12), OrsoBio ($67M, 2024-09-06), and Cognoa ($73M, 2022-11-14), indicating frequent mid-to-late stage labeling compared with single-use stages.
Are there outliers on the low end worth flagging alongside the high-end rounds?
Yes. Several very small disclosed rounds sit near the floor of disclosed amounts: Epalex at $1M (2025-11-10) and Greenstone Biosciences at $3M (2023-09-12). These low-end deals contrast sharply with the top end led by $500M (BridgeBio Pharma, 2025-02-25; Ascendis Pharma, 2022-03-24), and with mid-high disclosed rounds like BBOT’s $261M (2025-08-11).
Which entries are the most recent in this list, and how large are they versus earlier rounds?
The most recent date shown is 2026-06-17 for Spot Biosystems at $40M, followed by Countable Labs at $26M on 2026-05-28 and Pumpkinseed Technologies at $20M on 2026-05-05. These recent disclosed amounts are well below the disclosed $500M outliers and also below BBOT’s $261M (2025-08-11), but align with the broader $10M–$70M band seen across multiple years.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.